A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 31
Summary
- Conditions
- Locally Advanced
- Unresectable
- Urothelial Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a randomized phase II study testing two different schedules of atezolizumab combined with gemcitabine and cisplatin chemotherapy (GC) in patients with metastatic urothelial carcinoma (mUC) who are eligible for cisplatin.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03093922
- Collaborators
- Ohio State University
- University of Chicago
- Genentech, Inc.
- Targos
- Investigators
- Principal Investigator: Samuel Funt, MD Memorial Sloan Kettering Cancer Center
Get Well Soon